DMK Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsDMK Pharmaceuticals

DMK Pharmaceuticals(DMK)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

No data

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

Aglatimagene besadenovec

renal cell carcinoma

,

colonic neoplasms

,

,

urethral neoplasms

,

transitional cell carcinoma

,

neuroendocrine carcinoma

,

,

,

non-small-cell lung carcinoma

,

urinary bladder neoplasms

,

urologic neoplasms

,

small cell lung carcinoma

,

breast neoplasms

,

,

,

neuroendocrine tumors

,

ovarian neoplasms

,

uterine cervical neoplasms

,

small cell carcinoma

,

,

triple negative breast neoplasms

,

colorectal neoplasms

,

hepatocellular carcinoma

,

liver neoplasms

,

squamous cell carcinoma

,

,

disease progression

,

squamous cell carcinoma of head and neck

,

,

pancreatic neoplasms

,

endometrial neoplasms

,

stomach neoplasms

,

head and neck neoplasms

,

esophageal neoplasms

,

ovarian epithelial carcinoma

,

neoplasm metastasis

,

hypersensitivity

,

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

prostatic hyperplasia

,

,

disease susceptibility

ovarian neoplasms

,

,

colonic neoplasms

,

neuroendocrine tumors

,

ovarian epithelial carcinoma

,

endocrine gland neoplasms

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use